The ARPA-H Precision Surgical Interventions (PSI) program will fund the development of novel technologies for precise cancer tumor removal, and applications are due September 21.
The PSI program could support the development of more affordable and accessible multi-modality focused ultrasound systems.
See our specifications, which could be helpful when designing new systems.
The companies will integrate Cordance Medical's NeuroAccess™ blood-brain barrier opening platform with EXACT Therapeutics' Acoustic Cluster Therapy technology.
The collaboration aims to enhance the efficacy and precision of drug therapies for patients with brain diseases, including tumors and neurodegenerative disorders.